Aurinia Pharmaceuticals saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 90 to 95.
This unique rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the best stocks often have an 80 or better RS Rating in the early stages of their moves.
Here Are 3 Keys For Successful Stock Investing
Aurinia Pharmaceuticals is now considered extended and out of buy range after clearing a 7.45 buy point in a first-stage flat base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Aurinia Pharmaceuticals reported 0% EPS growth in its most recent report, while sales growth came in at 24%.
The company holds the No. 5 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the top-ranked stock within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
